首页>
外国专利>
BIOMARKER FOR DETERMINING MALIGNANCY OF CANCER, AND PROGNOSIS AND/OR EFFECTIVENESS OF ANTICANCER AGENT TREATMENT, COMPANION DIAGNOSTIC AGENT FOR SELECTING ANTICANCER AGENT, AS WELL AS ANTICANCER AGENT
BIOMARKER FOR DETERMINING MALIGNANCY OF CANCER, AND PROGNOSIS AND/OR EFFECTIVENESS OF ANTICANCER AGENT TREATMENT, COMPANION DIAGNOSTIC AGENT FOR SELECTING ANTICANCER AGENT, AS WELL AS ANTICANCER AGENT
PROBLEM TO BE SOLVED: To provide a biomarker for determining the malignancy of cancer, and the prognosis and/or effectiveness of an anticancer agent treatment, to provide a method for determining, using miR, the malignancy of cancer, and the prognosis and/or effectiveness of the anticancer agent treatment, as well as to provide a companion diagnostic agent or anticancer agent containing miR.SOLUTION: The invention relates to a method of using a biomarker that can determine the malignancy of cancer, and the prognosis and/or the effectiveness of anticancer agent treatment, while considering a patient's immune status, the biomarker being one or more kinds of microRNAs that exhibit a characteristic expression pattern in a patient with an IL-6 high expression level in blood. The invention also relates to a biomarker that can utilize, as anticancer agents, either a specified miR, and an inhibitory nucleic acid against this or a functional equivalent thereof that can inhibit the growth of cancer cells by being introduced into the cancer cells.SELECTED DRAWING: Figure 1
展开▼
